Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.36 |
| ▸ | FABP7 | O15540 | 2/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GRB2 | P62993 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247201 | 0.91 | KMT2A (0.43) | KMT2APTPN1CASP3FABP5FABP7 | |
| SCHEMBL2254025 | 0.90 | KMT2A (0.40) | KMT2APTPN1CASP3FABP5FABP7 | |
| SCHEMBL2246530 | 0.86 | PTPN1 (0.39) | KMT2APTPN1CASP3FABP5FABP7 | |
| SCHEMBL2248528 | 0.83 | KMT2A (0.42) | KMT2APTPN1CASP3FABP5FABP7 | |
| SCHEMBL29047040 | 0.82 | KMT2A (0.45) | KMT2APTPN1CASP3FABP5FABP7 | |
| SCHEMBL18832276 | 0.82 | KMT2A (0.45) | KMT2APTPN1CASP3FABP5FABP7 | |
| SCHEMBL2247134 | 0.82 | KMT2A (0.43) | KMT2APTPN1CASP3FABP5FABP7 | |
| SCHEMBL29047057 | 0.81 | KMT2A (0.44) | KMT2APTPN1CASP3FABP5FABP7 | |
| SCHEMBL2246665 | 0.81 | KMT2A (0.41) | KMT2APTPN1CASP3FABP5FABP7 | |
| SCHEMBL30074272 | 0.78 | KMT2A (0.39) | KMT2ACASP3FABP5FABP7MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | KMT2A 2364/4885PTPN1 4403/4885CASP3 2787/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | KMT2A 2364/4885PTPN1 4403/4885CASP3 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.